insulin glargine-yfgn 100 UNT/ML Injectable Solution [Semglee]
insulin glargine-yfgn
RxCUI: 2563977
What the CMS Formulary Data Shows for insulin glargine-yfgn 100 UNT/ML Injectable Solution [Semglee]
Per the CMS 2026 Part D formulary file, insulin glargine-yfgn 100 UNT/ML Injectable Solution [Semglee] (RxNorm concept RXCUI 2563977, generic name insulin glargine-yfgn) appears on 2 distinct formulary files spanning 3 Medicare Part D plan offerings - 0.1% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 1 to Tier 3, with a cross-plan average of Tier 2.
Real-world access to insulin glargine-yfgn 100 UNT/ML Injectable Solution [Semglee] depends on utilization management as much as tier placement: 0% of covering formularies require prior authorization. 0% require step therapy. 50% apply quantity limits.
Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 122,201 Part D beneficiaries filled insulin glargine-yfgn 100 UNT/ML Injectable Solution [Semglee] in 2023, with total plan-and-beneficiary spending of $32,270,212 and an average per-beneficiary annual cost of $264.07. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry insulin glargine-yfgn 100 UNT/ML Injectable Solution [Semglee] today.
Coverage Details
- Formularies covering
- 2
- Plans covering
- 3
- Coverage rate
- 0.1%
- Tier range
- Tier 1 – Tier 3
- Average tier
- Tier 2, Generic
Restrictions
- Prior authorization required
- 0% of formularies
- Step therapy required
- 0% of formularies
- Quantity limits
- 50% of formularies
2023 Medicare Spending
- Beneficiaries
- 122,201
- Total spending
- $32,270,212
- Avg per beneficiary
- $264.07
Tier Distribution Across Plans
Medicare Advantage Plans (MA-PD) Covering insulin glargine-yfgn 100 UNT/ML Injectable Solution [Semglee]
3 Medicare Advantage plans with Part D drug coverage include this drug.
| Plan | Insurer | Tier | PA | Premium | States |
|---|---|---|---|---|---|
| CCA One Care (HMO D-SNP) | COMMONWEALTH CARE ALLIANCE, INC. | T1 | No | $0 | MA |
| CCA Senior Care Options (HMO D-SNP) | COMMONWEALTH CARE ALLIANCE, INC. | T1 | No | $0 | MA |
| Mass Advantage Extra (PPO) | CENTRAL MASS HEALTH, LLC | T3 | No | $0 | MA |
Frequently Asked Questions
Is insulin glargine-yfgn 100 UNT/ML Injectable Solution [Semglee] covered by Medicare Part D?
Yes, insulin glargine-yfgn 100 UNT/ML Injectable Solution [Semglee] is covered by 3 Medicare Part D plans (0.1% of all Part D formularies).
What tier is insulin glargine-yfgn 100 UNT/ML Injectable Solution [Semglee] on Medicare Part D plans?
insulin glargine-yfgn 100 UNT/ML Injectable Solution [Semglee] averages Tier 2 across Part D plans, ranging from Tier 1 to Tier 3.
Does insulin glargine-yfgn 100 UNT/ML Injectable Solution [Semglee] require prior authorization?
0% of Part D formularies require prior authorization for insulin glargine-yfgn 100 UNT/ML Injectable Solution [Semglee]. Step therapy: 0%. Quantity limits: 50%.
How much does Medicare spend on insulin glargine-yfgn 100 UNT/ML Injectable Solution [Semglee]?
In 2023, total Medicare Part D spending on insulin glargine-yfgn 100 UNT/ML Injectable Solution [Semglee] was $32,270,212, covering 122,201 beneficiaries. The average spend per beneficiary was $264.07.
Read our methodology - how this data is sourced, computed, and verified.